Compare KPTI & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Kandi Technologies Group Inc is engaged in the development, production, and distribution of electric vehicle (EV) products, EV parts, and off-road vehicle products in the Chinese market. Other product offerings include all-terrain vehicles, go-karts, utility vehicles, battery packs, and other systems. It generates maximum revenue through off-road vehicles. The company generates the majority of its revenue from the United states along with other Countries, followed by China.